MA39803A - Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation - Google Patents

Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation

Info

Publication number
MA39803A
MA39803A MA039803A MA39803A MA39803A MA 39803 A MA39803 A MA 39803A MA 039803 A MA039803 A MA 039803A MA 39803 A MA39803 A MA 39803A MA 39803 A MA39803 A MA 39803A
Authority
MA
Morocco
Prior art keywords
influenza
methods
virus hemagglutinin
hemagglutinin antibodies
antibodies
Prior art date
Application number
MA039803A
Other languages
English (en)
Inventor
Mercedesz Balazs
Ning Chai
Nancy Chiang
Henry Chiu
Zhonghua Lin
Gerald R Nakamura
Hyunjoo Park
Lee Swem
Min Xu
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of MA39803A publication Critical patent/MA39803A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des anticorps hémagglutinine dirigés contre le virus de la grippe b, des compositions comprenant les anticorps dirigés contre l'hémagglutinine du virus de la grippe b, et des méthodes d'utilisation de celles-ci.
MA039803A 2014-03-27 2015-03-26 Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation MA39803A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27

Publications (1)

Publication Number Publication Date
MA39803A true MA39803A (fr) 2017-02-01

Family

ID=52829396

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039803A MA39803A (fr) 2014-03-27 2015-03-26 Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation

Country Status (20)

Country Link
US (2) US9745365B2 (fr)
EP (1) EP3122771A1 (fr)
JP (1) JP2017512471A (fr)
KR (1) KR20160135830A (fr)
CN (1) CN106132987A (fr)
AR (1) AR099855A1 (fr)
AU (1) AU2015235983A1 (fr)
BR (1) BR112016022113A2 (fr)
CA (1) CA2942820A1 (fr)
CL (2) CL2016002413A1 (fr)
CR (1) CR20160502A (fr)
EA (1) EA201691945A1 (fr)
IL (1) IL247870A0 (fr)
MA (1) MA39803A (fr)
MX (1) MX2016012530A (fr)
PE (1) PE20161376A1 (fr)
PH (1) PH12016501873A1 (fr)
SG (1) SG11201607945UA (fr)
TW (1) TW201620932A (fr)
WO (1) WO2015148806A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013683A (es) 2016-05-10 2019-06-17 Genentech Inc Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
SG11202106523SA (en) 2018-12-21 2021-07-29 Genentech Inc Targeted integration of nucleic acids
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
BR112022007923A2 (pt) * 2019-10-28 2022-07-26 Regeneron Pharma Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
IL294989A (en) * 2020-01-24 2022-09-01 Regeneron Pharma Conjugated protein-antiviral compounds
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
US20220041672A1 (en) 2020-06-24 2022-02-10 Genentech, Inc. Apoptosis resistant cell lines
IL299120A (en) 2020-06-24 2023-02-01 Genentech Inc A targeted combination of nucleic acids
CN116648507A (zh) 2020-08-28 2023-08-25 基因泰克公司 宿主细胞蛋白的CRISPR/Cas9多重敲除
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
WO2022225880A1 (fr) 2021-04-19 2022-10-27 Genentech, Inc. Cellules mammifères modifiées
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
EP4619413A2 (fr) 2022-11-14 2025-09-24 Janssen Vaccines & Prevention B.V. Vaccins contre le virus de la grippe b et leurs utilisations
EP4619511A1 (fr) 2022-11-15 2025-09-24 Genentech, Inc. Intégration médiée par transposon combinée et intégration ciblée d'acides nucléiques dans des cellules hôtes
EP4649148A1 (fr) 2023-01-12 2025-11-19 Genentech, Inc. Stratégies de clonage et de transfection de vecteur combinatoire pour intégration ciblée d'acides nucléiques
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
EP2380976A4 (fr) 2008-12-25 2012-11-07 Univ Osaka Anticorps humain anti-virus de la grippe humaine
US8961978B2 (en) * 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
WO2013114885A1 (fr) * 2012-01-31 2013-08-08 Osaka University Anticorps monoclonaux humains protecteurs à large spectre contre le virus de la grippe b et méthodes d'utilisation correspondantes
KR102050615B1 (ko) 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도

Also Published As

Publication number Publication date
AR099855A1 (es) 2016-08-24
MX2016012530A (es) 2017-01-05
CL2018002874A1 (es) 2018-12-14
IL247870A0 (en) 2016-11-30
WO2015148806A1 (fr) 2015-10-01
CL2016002413A1 (es) 2017-06-23
PH12016501873A1 (en) 2017-01-09
PE20161376A1 (es) 2016-12-26
EP3122771A1 (fr) 2017-02-01
CA2942820A1 (fr) 2015-10-01
KR20160135830A (ko) 2016-11-28
SG11201607945UA (en) 2016-10-28
US20150274812A1 (en) 2015-10-01
BR112016022113A2 (pt) 2017-10-31
EA201691945A1 (ru) 2017-02-28
TW201620932A (zh) 2016-06-16
JP2017512471A (ja) 2017-05-25
US20170320937A1 (en) 2017-11-09
US9745365B2 (en) 2017-08-29
CN106132987A (zh) 2016-11-16
AU2015235983A1 (en) 2016-10-06
CR20160502A (es) 2017-02-03

Similar Documents

Publication Publication Date Title
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EA201790630A1 (ru) Способы получения рибозидов
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MA40576A (fr) Anticorps et immunoconjugués anti-her2
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MX2015016755A (es) Reagrupamiento del virus de influenza.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
EP3939604A3 (fr) Vaccins contre la grippe à base de protéine hémagglutinine
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения